Evidence map›Paper›PMID 31632074›Full record

ArticleOncoTargets and therapy2019

Association Between Genetic Polymorphisms In

Li Yao, Linghui Zhou, Yujiao Deng, Yi Zheng, Pengtao Yang, Meng Wang, Shanshan Dong, Qian Hao, Peng Xu, Na Li and 4 more

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. TheInfection and drug resistance · 2021
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Li Yao *Department of Neurology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, People's Republic of China.
Linghui Zhou *Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, People's Republic of China.ORCID 0000-0002-4524-6114
Yujiao Deng *Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, People's Republic of China.ORCID 0000-0002-8124-9400
Yi ZhengDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, People's Republic of China.
Pengtao YangDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, People's Republic of China.
Meng WangDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, People's Republic of China.
Shanshan DongSchool of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049, People's Republic of China.
Qian HaoDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, People's Republic of China.
Peng XuDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, People's Republic of China.ORCID 0000-0002-8284-5730
Na LiDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, People's Republic of China.
Ying WuDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, People's Republic of China.
Zhen ZhaiDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, People's Republic of China.
Lijuan LyuDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, People's Republic of China.
Zhijun DaiDepartment of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, People's Republic of China.ORCID 0000-0001-5209-8626
Second Affiliated Hospital of Xi'an Jiaotong University · CNXi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThymidylate synthase (

methodsThis case-control study included 605 patients and 1300 cancer-free individuals. Genotyping was performed using Sequenom Mass-ARRAY. We determined odds ratios (ORs) and their 95% confidence intervals (CIs) to estimate the correlations.

resultsThe analysis revealed that rs1059394 TT and CT+TT genotype had significantly low glioma risk (TT to CC: OR = 0.71, 95% CI = 0.52-0.97,

conclusionOur study provides evidence of the effect of

Indexed as

case-control studygene variantgliomasusceptibilityTYMS

Identifiers

PMID31632074
PMCPMC6790345
OpenAlexW2979158860

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.